FIELD: chemistry.
SUBSTANCE: invention relates to a method of producing an amorphous solid dispersion containing a pharmaceutical substance as an active substance N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide, and as a polymer, additives are acceptable in pharmaceutical technology, according to which mixture containing 1 g of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide, polyvinylpyrrolidone polymer (15–20 g) or PEG 6000/vinylcaprolactam/vinyl acetate (15–20 g), at a weight ratio of 1:15–20, is dissolved in 34–96% ethanol (30–35 g), the obtained solution is dried at 40–65°C in a drying cabinet for 8–12 hours.
EFFECT: novel method of producing an amorphous solid dispersion containing a pharmaceutical substance as an active substance N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide, which enables to obtain N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide from a crystalline into an amorphous state and improve the solubility and pharmaceutical bioavailability of tablets based thereon.
1 cl, 6 dwg, 2 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION BASED ON N-BUTYL-N-METHYL-1-PHENYLPYRROLO[1,2-a]PYRAZINE-3-CARBOXAMIDE | 2023 |
|
RU2811453C1 |
PHARMACEUTICAL COMPOSITION BASED ON N-BENZYL-N-METHYL-1-PHENYLPYRROLO [1,2-A] PYRAZINE-3-CARBOXAMIDE | 2017 |
|
RU2689396C2 |
SOLID DISPERSION of 4- (3-ETHOXY-4-HYDROXIBENZIL) -5-OXO-5,6-DIHYDRO-4H- [1,3,4] -THIADIAZINE-2- (2,4-DIFLUOROPHENYL) -CARBOXAMIDE FOR PRODUCING PHARMACEUTICAL FORMULATION AND METHOD OF TREATMENT OF CHRONIC INFECTIOUS DISEASES | 2020 |
|
RU2743927C1 |
1-ARYLPYRROLO[1,2A]PYRAZINE-3-CARBOXAMIDES WITH NEUROPSYCHOTROPIC ACTIVITY | 2014 |
|
RU2572076C2 |
LIGANDS OF TRANSLOCATOR PROTEIN TSPO, HAVING ANTIDEPRESSANT AND NOOTROPIC ACTIVITY | 2015 |
|
RU2699568C2 |
DIPHENYLPYRROLO[1,2-A]PYRAZINE-3-CARBOXAMIDES-COMPOUNDS HAVING NEUROPSYCHOTROPIC ACTIVITY, METHODS FOR PREPARING THEM | 2018 |
|
RU2734240C2 |
SOLID PHARMACEUTICAL COMPOSITION FOR MANUFACTURE OF ORAL THERAPEUTIC AGENT FOR PREVENTION AND/OR TREATMENT OF HIV INFECTION | 2021 |
|
RU2759544C1 |
PYRROLO[1,2-A]PYRAZINE-CONTAINING LIGANDS OF THE 18 KDA TRANSLOCATOR PROTEIN WITH ANXIOLYTIC ACTIVITY | 2022 |
|
RU2812083C2 |
METHOD FOR PRODUCING AN AMORPHOUS FORM OF N-[2-(DIETHYLAMINO)ETHYL]-5-[(Z)-(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOLE-3-YLIDENE)METHYL]-2,4-DIMETHYL-1H-PYRROL-3-CARBOXAMIDE MALATE, PRODUCT AND APPLICATION THEREOF FOR TREATING ONCOLOGICAL AND IMMUNOLOGICAL DISEASES | 2021 |
|
RU2774382C1 |
N-FORMYL HYDROXYAMINE DERIVATIVES | 2006 |
|
RU2412939C2 |
Authors
Dates
2024-07-23—Published
2023-04-11—Filed